Amanda Tufman
About
Amanda Tufman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Amanda Tufman has authored 134 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Pulmonary and Respiratory Medicine, 76 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Amanda Tufman's work include Lung Cancer Treatments and Mutations (65 papers), Lung Cancer Diagnosis and Treatment (47 papers) and Cancer Immunotherapy and Biomarkers (28 papers). Amanda Tufman is often cited by papers focused on Lung Cancer Treatments and Mutations (65 papers), Lung Cancer Diagnosis and Treatment (47 papers) and Cancer Immunotherapy and Biomarkers (28 papers). Amanda Tufman collaborates with scholars based in Germany, United States and Switzerland. Amanda Tufman's co-authors include Rudolf M. Huber, Claus Belka, Farkhad Manapov, Diego Kauffmann‐Guerrero, Chukwuka Eze, Rainald Fischer, Petra Hoffknecht, Kathrin Kahnert, Julian Taugner and Lukas Käsmann and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
In The Last Decade
Amanda Tufman
107 papers receiving 1.9k citations
Peers
Amanda Tufman
Jean Trédaniel France
Édouard Auclin France
Cecilia Menna Italy
Rajesh Bandekar United States
Alessia Nottegar Italy
S. Machtens Germany
Philip J. Saylor United States
Jianmin Xu China
Sabine Schmid Switzerland
Christophe Leux France
Citations per year, relative to Amanda Tufman Amanda Tufman (= 1×)
peers
Jean Trédaniel
Countries citing papers authored by Amanda Tufman
Since
Specialization
Citations
This map shows the geographic impact of Amanda Tufman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Tufman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Tufman more than expected).
Fields of papers citing papers by Amanda Tufman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Amanda Tufman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Tufman. The network helps show where Amanda Tufman may publish in the future.
Co-authorship network of co-authors of Amanda Tufman
This figure shows the co-authorship network connecting the top 25 collaborators of Amanda Tufman. A scholar is included among the top collaborators of Amanda Tufman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda Tufman. Amanda Tufman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhao, Jun, Amanda Tufman, Lecia V. Sequist, et al.. (2025). OA08.03 COMPEL: Osimertinib + Platinum-Based Chemotherapy in Patients With EGFRm Advanced NSCLC and Progression on 1L Osimertinib. Journal of Thoracic Oncology. 20(10). S27–S27.
2.
Walter, Julia, Lena M. Unterrainer, Diego Kauffmann‐Guerrero, et al.. (2025). Elevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor–related pneumonitis in lung cancer patients. Frontiers in Oncology. 15. 1563030–1563030.
3.
Kepesidis, Kosmas V., Frank Fleischmann, Ina Koch, et al.. (2025). Assessing lung cancer progression and survival with infrared spectroscopy of blood serum. BMC Medicine. 23(1). 101–101.
4.
Walter, Julia, Christine Schmid‐Tannwald, Matthias Brendel, et al.. (2024). The Association between the Body Mass Index, Chronic Obstructive Pulmonary Disease and SUV of the Non-Tumorous Lung in the Pretreatment [18F]FDG-PET/CT of Patients with Lung Cancer. Diagnostics. 14(11). 1139–1139.
5.
Stüber, Anna Theresa, Matthias P. Fabritius, Boj Hoppe, et al.. (2024). Replication study of PD-L1 status prediction in NSCLC using PET/CT radiomics. European Journal of Radiology. 183. 111825–111825.
6.
Jonigk, Danny, et al.. (2024). Neoadjuvante Therapie des resektablen, nicht-kleinzelligen Lungenkarzinoms. Pneumologie. 79(1). 16–24.
7.
Kahnert, Kathrin, et al.. (2023). Hyperinflation and reduced diffusing capacity predict prognosis in SCLC: value of extended pre-therapeutic lung function testing. Therapeutic Advances in Respiratory Disease. 17. 2683778998–2683778998.
8.
Holzgreve, Adrien, Hans Roland Dürr, Axel Stäbler, et al.. (2023). Finger Pain as an Uncommon Primary Manifestation of Lung Carcinoma. Diagnostics. 13(5). 901–901.
9.
Walter, Julia, Diego Kauffmann‐Guerrero, Thomas Muley, et al.. (2023). Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients. Cancer Medicine. 12(7). 8880–8896.
10.
Taugner, Julian, Lukas Käsmann, Amanda Tufman, et al.. (2022). Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis. Journal of Cancer Research and Clinical Oncology. 149(7). 3267–3276.
11.
Tufman, Amanda, Jens Neumann, Farkhad Manapov, et al.. (2021). Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). Lung Cancer. 160. 17–27.
12.
Peters, Solange, Enriqueta Felip, Urania Dafni, et al.. (2020). Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). Journal of Thoracic Oncology. 16(2). 278–288.
13.
Käsmann, Lukas, Julian Taugner, Chukwuka Eze, et al.. (2019). Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment. Anticancer Research. 39(9). 5077–5081.
14.
Kauffmann‐Guerrero, Diego, Kathrin Kahnert, Jörg Kumbrink, et al.. (2018). Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib. Clinical Lung Cancer. 20(1). 59–62.
15.
Tufman, Amanda, Joachim von Pawel, Achim Rittmeyer, et al.. (2017). Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial. OncoTargets and Therapy. Volume 10. 1081–1089.
16.
Hoffknecht, Petra, Amanda Tufman, Thomas Wehler, et al.. (2014). Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease. Journal of Thoracic Oncology. 10(1). 156–163.
17.
Tufman, Amanda, et al.. (2014). Feasibility of microRNA Measurements in Routine Bronchoalveolar Lavage (BAL) and Bronchial Washings in Patients With Lung Cancer and Nonmalignant Pulmonary Diseases. CHEST Journal. 145(3). 342A–342A.
18.
Kobold, Sebastian, Till S. Clauditz, Sarah Minner, et al.. (2013). Interleukin-22 Is Frequently Expressed in Small- and Large-Cell Lung Cancer and Promotes Growth in Chemotherapy-Resistant Cancer Cells. Journal of Thoracic Oncology. 8(8). 1032–1042.
19.
Tufman, Amanda, M. Edelmann, Fernando Gamarra, et al.. (2013). Preselection Based on Clinical Characteristics in German Non–Small-Cell Lung Cancer Patients Screened for EML4-ALK Translocation. Journal of Thoracic Oncology. 9(1). 109–113.
20.
Pratschke, Sebastian, M Bilzer, U Grützner, et al.. (2011). Tacrolimus Preconditioning of Rat Liver Allografts Impacts Glutathione Homeostasis and Early Reperfusion Injury. Journal of Surgical Research. 176(1). 309–316.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jean Trédaniel Breakdown of academic impact, for papers by Édouard Auclin Breakdown of academic impact, for papers by Cecilia Menna Breakdown of academic impact, for papers by Rajesh Bandekar Breakdown of academic impact, for papers by Alessia Nottegar Breakdown of academic impact, for papers by S. Machtens Breakdown of academic impact, for papers by Philip J. Saylor Breakdown of academic impact, for papers by Jianmin Xu Breakdown of academic impact, for papers by Sabine Schmid Breakdown of academic impact, for papers by Christophe Leux